Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from CStone Pharmaceuticals ( (HK:2616) ).
CStone Pharmaceuticals announced that its bispecific antibody CS2015, targeting OX40L and TSLP, will be showcased at the ACAAI 2025 Annual Scientific Meeting in Orlando. This novel therapeutic agent aims to address Type 2 inflammatory diseases such as atopic dermatitis, asthma, and COPD. The presentation highlights CStone’s strategic focus on innovative treatments for autoimmune and inflammation conditions, potentially enhancing its market position and offering new solutions for patients.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. CStone’s pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines. The company is dedicated to addressing unmet medical needs in China and globally.
Average Trading Volume: 21,849,519
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.44B
For a thorough assessment of 2616 stock, go to TipRanks’ Stock Analysis page.